NVDA
NVIDIA Corporation
NVDA's fundamentals are strong and it looks cheap: trading at 21x earnings, about a third of its usual 65x. Analysts expect strong earnings growth.
SANG
Sangoma Technologies Corporation
There isn't enough reported data to score SANG yet.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
SANG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Under pressure |
SANG's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
SANG PE Valuation
SANG has no meaningful PE right now: it lost money over the past year.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
SANG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| -- |
Analysts expect SANG's losses to shrink, with revenue holding steady.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the stronger earnings trend. Trailing diluted EPS is up 125% for NVDA versus SANG down 400%.
SANG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.15 | +$0.11 |
| Q2 2024 | -$0.26 | +$0.62 |
| Q2 2023 | -$0.88 | +$2.64 |
| Q2 2022 | -$3.52 | -7140% |
| Q2 2021 | $0.05 | -80% |
| Q1 2021 | $0.27 | +17% |
| Q4 2020 | $0.49 | +123% |
| Q3 2020 | $0.29 | 0% |
SANG has swung to a loss: it lost $0.15 per share over the past year, after a profit the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
SANG has the stronger quarterly revenue trend. Revenue is up 106% for NVDA versus up 558% for SANG.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA's operating margin was 66% last quarter, up 5.4 points from the same quarter a year ago, near the top of its range since 2019.
SANG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $236.7M | -4.3% |
| Q2 2024 | $247.3M | -2.1% |
| Q2 2023 | $252.5M | +13% |
| Q2 2022 | $224.4M | +524% |
| Q2 2021 | $36M | +82% |
| Q1 2021 | $19.7M | +9.2% |
| Q4 2020 | $19M | +9.6% |
| Q3 2020 | $18.4M | +24% |
SANG's revenue has grown year over year for 21 quarters in a row: $237M last quarter, up 558% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -2.7% | +0.9 points |
| Q2 2024 | -3.8% | -12 points |
| Q2 2023 | -13% | -23 points |
| Q2 2022 | -47% | -56 points |
| Q2 2021 | -3.6% | -12 points |
| Q1 2021 | 8.4% | -0.3 points |
| Q4 2020 | 10% | +2.8 points |
| Q3 2020 | 9.7% | +3.9 points |
SANG's operating margin was −2.7% last quarter, up 0.9 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
SANG has the stronger cash trend. Its trailing FCF is up 1,063% versus its history, compared with NVDA at up 290%.
SANG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | $39.4M | -1.8% |
| Q2 2024 | $40.1M | +79% |
| Q2 2023 | $22.5M | +17% |
| Q2 2022 | $19.2M | +570% |
| Q2 2021 | $2.9M | -48% |
| Q1 2021 | $1.7M | +83% |
| Q4 2020 | $3.4M | +$5.4M |
| Q3 2020 | $1.7M | +33% |
SANG generated $121M in free cash flow over the past year, more than ten times what it generated the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over SANG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
SANG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +247K shares |
| 1 year | +76% | +14.5M shares |
| 3 years | +331% | +25.7M shares |
| 5 years | +621% | +28.9M shares |
| Available history | +578% | +28.6M shares |
SANG has 33M diluted shares, up 76% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $2.8M |
| Q2 2023 | $559,000 |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
SANG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 2.9x | Moderate |
| Q1 2021 | 4.1x | High |
| Q4 2020 | -1.6x | Net Cash |
| Q3 2020 | -1.7x | Net Cash |
| Q2 2020 | 2.0x | Healthy |
| Q1 2020 | 2.7x | Moderate |
| Q4 2019 | 3.1x | Elevated |
| Q3 2019 | 0.3x | Very low |
SANG's net debt is about 2.9 years of its operating earnings (EBITDA), up from 2.0 years a year ago.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
SANG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 76.3 | Neutral |
SANG's weekly RSI is 61 (neutral) and its Stochastic is 76 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
SANG PE vs Technology Sector
| Metric | SANG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SANG has no meaningful PE right now: it lost money over the past year.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
SANG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.60 | 3.7% above |
| 20 week MA | $4.18 | 14% above |
| 50 week MA | $4.29 | 11% above |
| 100 week MA | $4.98 | 4.2% below |
| 200 week MA | $4.63 | 3% above |
SANG has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.
SANG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.3 | $18.1 | +36% |
| 2021 | $18.1 | $16.7 | -7.7% |
| 2022 | $16.7 | $3.79 | -77% |
| 2023 | $3.79 | $3.20 | -16% |
| 2024 | $3.20 | $7.00 | +119% |
| 2025 | $7.00 | $5.03 | -28% |
| 2026 YTD | $5.03 | $4.77 | -5.2% |
SANG has the edge over NVDA on returns for 2026, with the stronger performance.